Cara Therapeutics, Inc. (NASDAQ:CARA) to Post FY2028 Earnings of ($0.21) Per Share, HC Wainwright Forecasts

Cara Therapeutics, Inc. (NASDAQ:CARA) – Equities research analysts at HC Wainwright issued their FY2028 earnings per share estimates for Cara Therapeutics in a research report issued to clients and investors on Friday, April 12th. HC Wainwright analyst O. Livnat expects that the biopharmaceutical company will post earnings of ($0.21) per share for the year. HC Wainwright currently has a “Buy” rating and a $2.50 price target on the stock. The consensus estimate for Cara Therapeutics’ current full-year earnings is ($1.25) per share.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Monday, March 4th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). Cara Therapeutics had a negative net margin of 565.21% and a negative return on equity of 122.10%. The business had revenue of $3.00 million during the quarter, compared to the consensus estimate of $2.34 million. During the same period in the prior year, the firm earned ($0.56) earnings per share.

Several other analysts have also recently weighed in on the company. Canaccord Genuity Group dropped their price objective on Cara Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, March 6th. Needham & Company LLC reissued a “buy” rating and set a $5.00 price objective on shares of Cara Therapeutics in a report on Wednesday, April 10th. Finally, StockNews.com cut Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $9.75.

Cara Therapeutics Stock Performance

Shares of NASDAQ:CARA opened at $0.71 on Monday. The stock has a market capitalization of $38.75 million, a P/E ratio of -0.33 and a beta of 0.70. Cara Therapeutics has a 1-year low of $0.50 and a 1-year high of $4.67. The business has a 50-day moving average price of $0.81 and a two-hundred day moving average price of $0.93.

Hedge Funds Weigh In On Cara Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CARA. Tower Research Capital LLC TRC grew its position in shares of Cara Therapeutics by 117.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,070 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 4,896 shares during the period. Mackenzie Financial Corp boosted its position in Cara Therapeutics by 71.2% during the 4th quarter. Mackenzie Financial Corp now owns 53,678 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 22,329 shares during the last quarter. Barclays PLC boosted its position in Cara Therapeutics by 717.7% during the 4th quarter. Barclays PLC now owns 64,012 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 56,184 shares during the last quarter. Two Sigma Securities LLC acquired a new position in Cara Therapeutics during the 1st quarter worth approximately $58,000. Finally, Profund Advisors LLC acquired a new position in Cara Therapeutics during the 1st quarter worth approximately $59,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.